United States securities and exchange commission logo

                             January 4, 2021

       Robert Ang, M.B.B.S.
       President and Chief Executive Officer
       Vor Biopharma Inc.
       100 Cambridgepark Drive
       Suite 400
       Cambridge, MA 02140

                                                        Re: Vor Biopharma Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted December
18, 2020
                                                            CIK No. 0001817229

       Dear Dr. Ang:

             We have reviewed your amended registration statement and have the
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
December 3, 2020 letter.

       Amendment No. 1 to Draft Registration Statement on Form S-1, Submitted
December 18, 2020

       Summary, page 1

   1.                                                   We note your response
to our prior comment number 1. Please revise your disclosure in
                                                        the Overview section to
clearly state that your lead candidate, VOR33 is preclinical. To
                                                        explain the novelty and
uniqueness of your approach and to highlight the associated
                                                        challenges, please also
revise the Overview to disclose that (i) engineered hematopoietic
                                                        stem cells have never
undergone clinical trials and (ii) the removal of CD33 from
                                                        hematopoietic stem
cells has never been studied in clinical trials.
 Robert Ang, M.B.B.S.
FirstName  LastNameRobert Ang, M.B.B.S.
Vor Biopharma   Inc.
January    NameVor Biopharma Inc.
        4, 2021
Page 2 4, 2021 Page 2
FirstName LastName
2.       We note your response to our prior comment number 4. On page 18 you
state that you
         have not yet filed an IND application for VOR33. Please revise pages 2
or 4 to state when
         you plan to submit an IND for VOR33 for AML.
Our Proprietary Vor Platform, page 2

3.       We note that your disclosure on page 3 highlights that you have a
highly efficient
         manufacturing process. Please revise page 3 to clarify the meaning of
this statement in
         light of your risk factor disclosure on page 39, where you state that
you "have not
         demonstrated that eHSCs or VCAR33 can be frozen and thawed in large
         without damage, in a cost-efficient manner and without degradation"
and, further, that you
         "may not be able to commercialize eHSCs, VCAR33 or other cell-based
         therapeutics we may develop on a large scale or in a cost-effective
Risk Factors
Development of a product candidate such as VOR33, which is intended for use in
combination or
in sequence with an already approved therapy.., page 27

4.       We note your response to prior comment 6. With reference to your
disclosure on page 28,
         please revise to clarify whether you will need to work with Pfizer to
satisfy the
         requirement that you reference in this risk factor. In this regard, it
should be clear whether
         you will need to negotiate a license and/or supply agreement so that
Mylotarg can be used
         in combination or in sequence with VOR33.
Business, page 121

5.       We note your response to our prior comment number 11. Please revise
pages 103 and 127
         to expressly state that your companion therapeutic VCAR33, which is
intended to be used
         in conjunction with VOR33, employs viral vectors.
       You may contact Eric Atallah at 202-551-3663 or Kevin Kuhar at
202-551-3662 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Margaret Schwartz at 202-551-7153 or Joe McCann at 202-551-6262 with
any other


                                                                Division of
Corporation Finance
                                                                Office of Life
cc:      Richard Segal, Esq.